CAL
GNMK

Capital Analysts LLC’s GenMark Diagnostics, Inc GNMK Stock Holding History

Capital Analysts LLC’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$3K – 833
2020
Q3 		$3K Hold
200
– – ﹤0.01% 699
2020
Q2 		$3K Buy
+200
New +$2.03K ﹤0.01% 655

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Analysts LLC's GNMK Position: Q4 2020 in Review

Capital Analysts LLC sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 200 shares — an estimated $3K sold.

Capital Analysts LLC first reported a position in GNMK in Q2 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Capital Analysts LLC reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 200 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $3K.
  • Capital Analysts LLC first reported a position in GenMark Diagnostics, Inc in Q2 2020 and held it in 2 quarters.
  • Capital Analysts LLC's GenMark Diagnostics, Inc position peaked at $3K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.